Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
This study is currently recruiting participants.
Verified December 2012 by M.D. Anderson Cancer Center
Study NCT01067066   Information provided by M.D. Anderson Cancer Center

First Received on February 9, 2010.   Last Updated on December 11, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
TPI 287
Temodar (Temozolomide)
Additional drug interventions recognized in this trial
Dacarbazine
Temozolomide
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Archer Biosciences, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services